<section id="dosing" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing active">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main class="dosing-adjustments">
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content">
        <a href="" ui-sref="DOSING-ADMINISTRATION" class="back-btn dosing">
            <i class="fas fa-arrow-circle-left"></i>
            <h5 class="dosing-header">BACK</h5>
        </a>
        <h3 class="dosing-header">DOSE ADJUSTMENTS</h3>
        <div class="img-wrapper">
            <img src="assets/dosing/dose-adjustments.png" alt="Dosing Adjustments Table" />
        </div>
        <!-- <div class="adjustments-table">
            <div class="col">
                <div class="row1">
                    <h5>Patients with or receiving:</h5>
                </div>
                <div class="row2">
                    <ul>
                        <li>Strong CYP3A4 inhibitor(s) (e.g., ketoconazole)</li>
                        <li>Moderate CYP3A4 inhibitor(s) with a strong CYP2C19 inhibitors (e.g., fluconazole)</li>
                    </ul>
                </div>
                <div class="row3">
                    <ul>
                        <li>Moderate or severe renal impairment</li>
                        <li>Moderate hepatic impairment<sup>a</sup></li>
                    </ul>
                </div>
                <div class="row4">
                    <ul>
                        <li>ANC 500 to 1000 cells/mm<sup>3</sup></li>
                    </ul>
                </div>
                <div class="row5">
                    <ul>
                        <li>ANC &lt;500 cells/mm<sup>3</sup></li>
                        <li>Lymphocyte count &lt;500
                            cells/mm<sup>3</sup>, confirmed by repeat
                            testing
                        </li>
                    </ul>
                </div>
                <div class="row6">
                    <ul>
                        <li>Hemoglobin &lt;8 g/dL or a
                            decrease of &gt;2 g/dLv</li>
                    </ul>
                </div>
            </div>
            <div class="col">
                <div class="row1">
                    <h5>Dosage adjustment</h5>
                </div>
                <div class="row2">
                    <p class="bold">XELJANZ/XELJAZ Oral Solution</p>
                    <p>If taking 3.2 mg twice daily, <br>reduce to 3.2 mg once daily</p>
                    <p>If taking 4 mg twice daily, <br>reduce to 4 mg once daily</p>
                    <p>If taking 5 mg twice daily, <br>reduce to 5 mg once daily</p>
                </div>
                <div class="row3">
                    <p>If taking 3.2 mg twice daily, <br>reduce to 3.2 mg once daily</p>
                    <p>If taking 4 mg twice daily, <br>reduce to 4 mg once daily</p>
                    <p>If taking 5 mg twice daily, <br>reduce to 5 mg once daily</p>
                </div>
                <div class="row4">
                    <ul>
                        <li>Interrupt dosing until ANC is
                            greater than 1000 cells/mm3</li>
                    </ul>
                </div>
                <div class="row5">
                    <ul>
                        <li>
                            Discontinue dosing
                        </li>
                    </ul>
                </div>
                <div class="row6">
                    <ul>
                        <li>Interrupt dosing until hemoglobin values have normalized</li>
                    </ul>
                </div>
            </div>
        </div> -->
        <p class="bottom-p">For patients undergoing hemodialysis, dose should be administered
            after the dialysis session on dialysis days. If a dose was taken before
            the dialysis procedure, supplemental doses are not recommended in
            patients after dialysis</p>
            <a href="" class="cyp-btn">List of CYP inhibitors <i class="fas fa-arrow-right"></i></a>
        <div class="footnotes">
            <ol>
                <li>Use of XELJANZ/XELJANZ XR/XELJANZ Oral Solution in patients with severe hepatic
                    impairment is not recommended.</li>
            </ol>
            <p>ANC=absolute neutrophil count; CYP=cytochrome P450.<br>
                XELJANZ/XELJANZ XR/XELJANZ Oral Solution [prescribing information]. New York, NY:
                Pfizer Inc; 2020.</p>
        </div>
    </div>
    </main>
</div>
<nav class="mobile">
    <a href="" ui-sref="MOA" class="moa">
        <i class="fas fa-atom"></i>
        <h5>MOA</h5>
    </a>
    <a href="" ui-sref="CT" class="ct">
        <i class="fas fa-users"></i>
        <h5>Clinical Trials</h5>
    </a>
    <a href="" ui-sref="EFFICACY" class="efficacy">
        <i class="fas fa-chart-line"></i>
        <h5>Efficacy</h5>
    </a>
    <a href="" ui-sref="SAFETY" class="safety">
        <i class="fas fa-exclamation-triangle"></i>
        <h5>Safety</h5>
    </a>
    <a href="" ui-sref="DOSING" class="dosing active">
        <i class="fas fa-prescription"></i>
        <h5>Dosing</h5>
    </a>
</nav>
</section>